Pretreatment with statins enhances myocardial protection during coronary revascularization

Journal of Thoracic and Cardiovascular Surgery

Volumn 125, Issue 5, 2003, Pages 1037-1042

  Lazar, Harold L ^a   Bao, Yusheng ^b   Zhang, Yu ^b   Bernard, Sheilah A ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BRADYKININ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CALCULATION; CARDIOVERSION; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HISTOCHEMISTRY; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SCORING SYSTEM; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 0038350975     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2003.177     Document Type: Article

References (18)

1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:401-7.
3. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
4. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenousvein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-62.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1995;335: 1001-9.
6. Albert MA, Danielson E, Rifa I. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP evaluation (PRINCE). A randomized trial and cohort study. JAMA. 2001;286:64-70.
7. Dechend R, Fiebler A, Park J-K, Muller DN, Theuer J, Mervaala E, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation. 2001;104:576-81.
8. Endres M, Laufs V, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880-5.
9. Lefer AM, Campbell B, Shin Y-K, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999;100:178-84.
10. Laufs V, La Fata V, Plutsky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-35.
11. Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q wave acute myocardial infarction. Am J Cardiol. 1998;81:578-81.
12. Lazar HL, Yang XM, Rivers S, Treanor P, Shemin RJ. Role of percutaneous bypass in infarct size following revascularization for acute coronary insufficiency. Circulation. 1991;84(Suppl):III416-21.
13. Wagner AH, Kohler T, Ruckschloss V, Just I, Hecker M. Improvement in nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-9.
14. Feron O, Dessy C, Desager JP, Belligard JL. HMG-CoA reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2000;103: 113-8.
15. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-31.
16. Weber C, Erl W, Weber KJC, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and Cd11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212-7.
17. Florens E, Salvi S, Peynet Pynet J, Elbim C, Mallat Z, Bel A, et al. Can statins reduce the inflammatory response to cardiopulmonary bypass? A Clinical Study. J Card Surg. 2001;16:232-9.
18. Chan AW, Bhatt DL, Chew DP, Quinn NJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691-6.